[Skip to Navigation]
JAMA Dermatology Clinical Evidence Synopsis
April 24, 2019

Evaluation of Ivermectin vs Permethrin for Treating Scabies—Summary of a Cochrane Review

Author Affiliations
  • 1Division of Evidence-Based Medicine, Department of Dermatology, Venereology, and Allergology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany
JAMA Dermatol. 2019;155(6):730-732. doi:10.1001/jamadermatol.2019.0279

Clinical Question  Is the use of ivermectin in patients infested with scabies associated with improved clinical and safety outcomes compared with permethrin?

Bottom Line  Both ivermectin and permethrin treatment were associated with high clearance rates. There is low-certainty evidence that ivermectin was associated with slightly lower rates of complete clearance after 1 week compared with permethrin, 5%, cream (relative risk [RR], 0.65; 95% CI, 0.54-0.78). After 2 weeks, there was no difference in efficacy (RR, 0.91; 95% CI, 0.76-1.08; low-certainty evidence), or in the number of participants with adverse events (week 4: RR, 1.30; 95% CI, 0.35-4.83; low-certainty evidence).

Add or change institution